UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Lancet neurology, 2013-08, Vol.12 (8), p.756-767

2013

Volltextzugriff (PDF)

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Lancet neurology, 2021-09, Vol.20 (9), p.729-738

2021

Volltextzugriff (PDF)

Variation in interleukin 7 receptor α chain ( IL7R ) influences risk of multiple sclerosis

Nature genetics, 2007-09, Vol.39 (9), p.1108-1113

2007

Volltextzugriff (PDF)

Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study

JAMA neurology, 2016-09, Vol.73 (9), p.1089

2016

Volltextzugriff (PDF)

Pivotal Advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis

Journal of leukocyte biology, 2008-11, Vol.84 (5), p.1248-1255

2008

Volltextzugriff (PDF)

Evolution of clinical trials in multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2019-02, Vol.12, p.1756286419826547-1756286419826547

2019

Volltextzugriff (PDF)

T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis

The Journal of immunology (1950), 2004-06, Vol.172 (11), p.7169-7176

2004

Volltextzugriff (PDF)

Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery?

Neurobiology of disease, 2010-03, Vol.37 (3), p.613-621

2010

Volltextzugriff (PDF)

Design of a Phase 2b Dose-finding Trial to Evaluate Safety and Efficacy of the CNS-penetrant BTK Inhibitor SAR442168 in Patients with Relapsing Forms of Multiple Sclerosis (804)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Autoimmunity to Myelin Oligodendrocyte Glycoprotein in Rats Mimics the Spectrum of Multiple Sclerosis Pathology

Brain pathology (Zurich, Switzerland), 1998-10, Vol.8 (4), p.681-694

1998

Volltextzugriff (PDF)

Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE

Journal of neuroinflammation, 2007-05, Vol.4 (1), p.14-14, Article 14

2007

Volltextzugriff (PDF)

Basic Immunological Profile Changes of SPMS Patients Treated with BAF312 (P1.384)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

Comparative Immunophenotyping and Gene Expression Analysis of Benign and Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial (P3.384)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

Genetics of autoimmune neuroinflammation

Current Opinion in Immunology, 2006-12, Vol.18 (6), p.643-649

2006

Volltextzugriff (PDF)

Vra4 Congenic Rats with Allelic Differences in the Class II Transactivator Gene Display Altered Susceptibility to Experimental Autoimmune Encephalomyelitis

The Journal of immunology (1950), 2008-03, Vol.180 (5), p.3289-3296

2008

Volltextzugriff (PDF)

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

The Lancet (British edition), 2018-03, Vol.391 (10127), p.1263-1273

2018

Volltextzugriff (PDF)

An Advanced Intercross Line Resolves Eae18 into Two Narrow Quantitative Trait Loci Syntenic to Multiple Sclerosis Candidate Loci

The Journal of immunology (1950), 2004-07, Vol.173 (2), p.1366-1373

2004

Volltextzugriff (PDF)

CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin

Journal of neuroinflammation, 2005-07, Vol.2 (1), p.17-17, Article 17

2005

Volltextzugriff (PDF)

The Use of a Short Acquisition Magnetization Transfer Ratio (MTR) Sequence in a Multicenter Clinical Trial of Siponimod (BAF312) in Relapsing–Remitting Multiple Sclerosis (P07.115)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

Safety and Efficacy of Siponimod (BAF312) in Patients with Relapsing-remitting Multiple Sclerosis: Results from Dose-blinded Extension Phase of BOLD Study (P3.151)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Eae19, a New Locus on Rat Chromosome 15 Regulating Experimental Autoimmune Encephalomyelitis

Genetics (Austin), 2005-05, Vol.170 (1), p.283-289

2005

Volltextzugriff (PDF)

Phase 2 BOLD Extension Study Efficacy Results for Siponimod (BAF312) in Patients with Relapsing–Remitting Multiple Sclerosis (P07.110)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

Phase 2 BOLD Extension Study Safety Results for Siponimod (BAF312) in Patients with Relapsing–Remitting Multiple Sclerosis (P01.176)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

Prior poliomyelitis-evidence of cytokine production in the central nervous system

Journal of the neurological sciences, 2002-12, Vol.205 (1), p.9-13

2002

Volltextzugriff (PDF)

Linkage Analysis of Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis in the Rat Identifies a Locus Controlling Demyelination on Chromosome 18

Human molecular genetics, 1999-11, Vol.8 (12), p.2183-2190

1999

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(69)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(43)
Life Sciences & Biomedicine
(40)
Medicin Och Hälsovetenskap
(36)
Female
(26)
Male
(26)
Humans
(24)
Animals
(19)
Neurosciences & Neurology
(19)
Rats
(17)
Immunology
(16)
Middle Aged
(16)
Multiple Sclerosis
(16)
Neurosciences
(14)
Myelin Proteins
(13)
Myelin-Oligodendrocyte Glycoprotein
(13)
Adult
(12)
Encephalomyelitis, Autoimmune, Experimental - Genetics
(11)
Clinical Neurology
(10)
Encephalomyelitis, Autoimmune, Experimental - Pathology
(10)
Aged
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Variation in interleukin 7 receptor α chain ( IL7R ) influences risk of multiple sclerosis

Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study

Pivotal Advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis

Evolution of clinical trials in multiple sclerosis

T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis

Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery?

Design of a Phase 2b Dose-finding Trial to Evaluate Safety and Efficacy of the CNS-penetrant BTK Inhibitor SAR442168 in Patients with Relapsing Forms of Multiple Sclerosis (804)

Autoimmunity to Myelin Oligodendrocyte Glycoprotein in Rats Mimics the Spectrum of Multiple Sclerosis Pathology

Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE

Basic Immunological Profile Changes of SPMS Patients Treated with BAF312 (P1.384)

Comparative Immunophenotyping and Gene Expression Analysis of Benign and Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial (P3.384)

Genetics of autoimmune neuroinflammation

Vra4 Congenic Rats with Allelic Differences in the Class II Transactivator Gene Display Altered Susceptibility to Experimental Autoimmune Encephalomyelitis

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

An Advanced Intercross Line Resolves Eae18 into Two Narrow Quantitative Trait Loci Syntenic to Multiple Sclerosis Candidate Loci

CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin

The Use of a Short Acquisition Magnetization Transfer Ratio (MTR) Sequence in a Multicenter Clinical Trial of Siponimod (BAF312) in Relapsing–Remitting Multiple Sclerosis (P07.115)

Safety and Efficacy of Siponimod (BAF312) in Patients with Relapsing-remitting Multiple Sclerosis: Results from Dose-blinded Extension Phase of BOLD Study (P3.151)

Eae19, a New Locus on Rat Chromosome 15 Regulating Experimental Autoimmune Encephalomyelitis

Phase 2 BOLD Extension Study Efficacy Results for Siponimod (BAF312) in Patients with Relapsing–Remitting Multiple Sclerosis (P07.110)

Phase 2 BOLD Extension Study Safety Results for Siponimod (BAF312) in Patients with Relapsing–Remitting Multiple Sclerosis (P01.176)

Prior poliomyelitis-evidence of cytokine production in the central nervous system

Linkage Analysis of Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis in the Rat Identifies a Locus Controlling Demyelination on Chromosome 18

Suchergebnisse filtern